Skip to main content
SpringerLink
Log in

Os, cible thérapeutique (RPC 2013)

  • Recommandations / Guidelines
  • Published:
Oncologie

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Références

  1. Albiges LMC, Loriot Y, Fizazi K (2012) Les thérapies ciblées de l’os métastatique: soins de support ou traitements de fond ? Oncologie 14(2): 103–107

    Article  CAS  Google Scholar 

  2. Amadori D, Aglietta M, Alessi B, et al. (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7): 663–670.

    Article  CAS  PubMed  Google Scholar 

  3. Barragan-Campos HM, Vallee JN, Lo D, et al. (2006) Percutaneous vertebroplasty for spinal metastases: complications. Radiology 238(1): 354–362.

    Article  PubMed  Google Scholar 

  4. Berenson J, Pflugmacher R, Jarzem P, et al. (2011) Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol 12(3): 225–235.

    Article  PubMed  Google Scholar 

  5. Body JJ, Lipton A, Gralow J et al. 2010 Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. JBMR 25(3):440–446

    Article  CAS  Google Scholar 

  6. Brufsky AM, Harker WG, Beck JT, et al. (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118(5): 1192–1201.

    Article  CAS  PubMed  Google Scholar 

  7. Calmels V, Vallee JN, Rose M, Chiras J (2007) Osteoblastic and mixed spinal metastases: evaluation of the analgesic efficacy of percutaneous vertebroplasty. AJNR Am J Neuroradiol 28(3): 570–574.

    CAS  PubMed  Google Scholar 

  8. Chang SD, Adler JR (2001) Robotics and radiosurgery: the cyberknife. Stereotact Funct Neurosurg 76(3–4): 204–208.

    Article  CAS  PubMed  Google Scholar 

  9. Chang SD, Adler JR Jr (2001) Current status and optimal use of radiosurgery. Oncology (Williston Park) 15(2): 209–216; discussion 19–21.

    CAS  Google Scholar 

  10. Chiras J, Adem C, Vallee JN, et al. (2004) Selective intra-arterial chemoembolization of pelvic and spine bone metastases. Eur Radiol 14(10): 1774–1780.

    Article  PubMed  Google Scholar 

  11. Chiras J, Depriester C, Weill A, et al. (1997) Percutaneous vertebral surgery. Technics and indications. J Neuroradiol 24(1): 45–59.

    CAS  PubMed  Google Scholar 

  12. Chiras J, Vallee JN, Lo D, Rose M (2005) Interventional radiology for bone metastases. In: Textbook of bone metastases. Chichester: John Wiley & Sons

    Google Scholar 

  13. Choi D, Crockard A, Bunger C, et al. (2010) Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the Global Spine Tumour Study Group. Eur Spine J 19(2): 215–222.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Clezardin P (2013) Physiopathologie des métastases osseuses et nouvelles cibles moléculaires impliquées dans le remodelage osseux. Bull Cancer. 100(11):1083–1091

    PubMed  Google Scholar 

  15. Coldwell DM, Sewell PE (2005) The expanding role of interventional radiology in the supportive care of the oncology patient: from diagnosis to therapy. Semin Oncol 32(2): 169–173.

    Article  PubMed  Google Scholar 

  16. Coleman R, de Boer R, Eidtmann H, et al. (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24(2): 398–405.

    Article  CAS  PubMed  Google Scholar 

  17. Coleman RE, Marshall H, Cameron D, et al. (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365(15): 1396–1405.

    Article  CAS  PubMed  Google Scholar 

  18. Coleman RE, Winter MC, Cameron D, et al. (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102(7): 1099–1105.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Coleman RWJ, Wright J, Houston S, et al. (2012) Randomised trial of marker-directed versus standard shedule zoledronic acid for bone metastases from breast cancer [Abstract]. J Clin Oncol: 30(Suppl): (Abstract 511)

    Google Scholar 

  20. Cotten A, Dewatre F, Cortet B, et al. (1996) Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up. Radiology 200(2): 525–530.

    CAS  PubMed  Google Scholar 

  21. de Freitas RM, de Menezes MR, Cerri GG, Gangi A (2011) Sclerotic vertebral metastases: pain palliation using percutaneous image-guided cryoablation. Cardiovasc Intervent Radiol 34(Suppl 2): S294–S299.

    Article  PubMed  Google Scholar 

  22. Debiais F (2013) Biomarkers of bone remodelling (Marqueurs biochimiques du remodelage osseux). Bull Cancer 100(11):1093–1100

    PubMed  Google Scholar 

  23. Deschamps F, Farouil G, Hakime A, et al. (2012) Percutaneous stabilization of impending pathological fracture of the proximal femur. Cardiovasc Intervent Radiol 35(6): 1428–1432.

    Article  PubMed  Google Scholar 

  24. Diel IJ, Jaschke A, Solomayer EF, et al. (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19(12): 2007–2011.

    Article  CAS  PubMed  Google Scholar 

  25. Diel IJ, Solomayer EF, Costa SD, et al. (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339(6): 357–363.

    Article  CAS  PubMed  Google Scholar 

  26. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M (2002) Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 20(9): 2382–2387.

    Article  CAS  PubMed  Google Scholar 

  27. Dupuy DE, Liu D, Hartfeil D, et al. (2010) Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial. Cancer 116(4): 989–997.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Eidtmann H, de Boer R, Bundred N, et al. (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21(11): 2188–2194.

    Article  CAS  PubMed  Google Scholar 

  29. Fisher CG, DiPaola CP, Ryken TC, et al. (2010) A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine 35(22): E1221–E1229.

    Article  PubMed  Google Scholar 

  30. Fizazi K, Lipton A, Mariette X et al. (2009) Randomized Phase II Trial of Denosumab in Patients With bone metastases from prostate cancer, breast cancer or other neoplasms after IV bisphsophonates. JCO 27(10):1564–1571

    Article  CAS  Google Scholar 

  31. Fourney DR, Schomer DF, Nader R, et al. (2003) Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 98(1 Suppl): 21–30.

    PubMed  Google Scholar 

  32. Gangi A, Guth S, Imbert JP, et al. (2003) Percutaneous vertebroplasty: indications, technique, and results. Radiographics 23(2): e10.

    Article  PubMed  Google Scholar 

  33. Gasbarrini A, Li H, Cappuccio M, et al. (2010) Efficacy evaluation of a new treatment algorithm for spinal metastases. Spine 35(15): 1466–1470.

    PubMed  Google Scholar 

  34. Gnant M, Mlineritsch B, Schippinger W, et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N England J Med 360(7): 679–691.

    Article  CAS  Google Scholar 

  35. Gnant M, Mlineritsch B, Stoeger H, et al. (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7): 631–641.

    Article  CAS  PubMed  Google Scholar 

  36. Gralow JR, Biermann JS, Farooki A, et al. (2013) NCCN Task Force Report: bone health in cancer care. J Natl Compr Canc Netw: JNCCN 11(Suppl 3): S1–S50; quiz S1.

    PubMed  Google Scholar 

  37. Ha TC, Li H (2007) Meta-analysis of clodronate and breast cancer survival. Br J Cancer 96(12): 1796–1801.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Hatoum HT, Lin SJ, Smith MR, et al. (2008) Zoledronic acid and skeletal complications in patients with solid tumours and bone metastases: analysis of a national medical claims database. Cancer 113(6): 1438–1445.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Kohno N, Aogi K, Minami H, et al. (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo-controlled trial. J Clin Oncol 23(15): 3314–3321.

    Article  CAS  PubMed  Google Scholar 

  40. Lane JM, Hong R, Koob J, et al. (2004) Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Relat Res (426): 49–53.

    Article  PubMed  Google Scholar 

  41. Lee BL, Higgins MJ, Goss PE (2012) Denosumab and the current status of bone-modifying drugs in breast cancer. Acta Oncol 51(2): 157–167.

    Article  CAS  PubMed  Google Scholar 

  42. Li H, Gasbarrini A, Cappuccio M, et al. (2009) Outcome of excisional surgeries for the patients with spinal metastases. Eur Spine J 18(10): 1423–1430.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Lipton A, Cook R, Saad F, et al. (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumours and elevated bone resorption receiving zoledronic acid. Cancer 113(1): 193–201.

    Article  CAS  PubMed  Google Scholar 

  44. Llombart A, Frassoldati A, Paija O, et al. (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12(1): 40–48.

    Article  CAS  PubMed  Google Scholar 

  45. Masala S, Lunardi P, Fiori R, et al. (2004) Vertebroplasty and kyphoplasty in the treatment of malignant vertebral fractures. J Chemother 16(Suppl 5): 30–33

    PubMed  Google Scholar 

  46. Milano MT, Katz AW, Zhang H, Okunieff P (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83(3): 878–886.

    Article  PubMed  Google Scholar 

  47. Patchell RA (2005) New developments in the surgical management of spinal cord compression caused by metastatic tumour. Clin Neurosurg 52: 65–67.

    PubMed  Google Scholar 

  48. Patchell RA, Tibbs PA, Regine WF, et al. (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366(9486): 643–648.

    Article  PubMed  Google Scholar 

  49. Paterson AH, Powles TJ, Kanis JA, et al. (1993) Double-blind trial of oral clodronate in breast cancer patients with bone metastases. Bull Cancer 80(10 Suppl): 50–56.

    CAS  PubMed  Google Scholar 

  50. Pereira LP, Clarencon F, Cormier E, et al. (2013) Safety and effectiveness of percutaneous sacroplasty: a single-centre experience in 58 consecutive patients with tumours or osteoporotic insufficient fractures treated under fluoroscopic guidance. Eur Radiol 23(10): 2764–2772.

    Article  PubMed  Google Scholar 

  51. Phillips FM, Todd-Wetzel F, Lieberman I, Campbell-Hupp M (2002) An in vivo comparison of the potential for extravertebral cement leak after vertebroplasty and kyphoplasty. Spine 27(19): 2173–2178; discussion 8–9

    Article  PubMed  Google Scholar 

  52. Powles T, Paterson A, McCloskey E, et al. (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res: BCR 8(2): R13.

    Article  PubMed  Google Scholar 

  53. Powles T, Paterson S, Kanis JA, et al. (2002) Randomised, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20(15): 3219–3224.

    Article  CAS  PubMed  Google Scholar 

  54. Rades D, Fehlauer F, Schulte R, et al. (2006) Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol 24(21): 3388–3393.

    Article  PubMed  Google Scholar 

  55. Radin EL, Rubin CT, Thrasher EL, et al. (1982) Changes in the bone-cement interface after total hip replacement. An in vivo animal study. J Bone Joint Surg Am 64(8): 1188–1200.

    CAS  PubMed  Google Scholar 

  56. Rosenthal D, Callstrom MR (2012) Critical review and state of the art in interventional oncology: benign and metastatic disease involving bone. Radiology 262(3): 765–780.

    Article  PubMed  Google Scholar 

  57. Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2): S150–S162.

    Article  PubMed  Google Scholar 

  58. Russell RG, Xia Z, Dunford JE, et al. (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117: 209–257.

    Article  CAS  PubMed  Google Scholar 

  59. Ryu SI, Chang SD, Kim DH, et al. (2001) Image-guided hypo-fractionated stereotactic radiosurgery to spinal lesions. Neurosurgery 49(4): 838–846.

    CAS  PubMed  Google Scholar 

  60. Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomised controlled trial. J Clin Oncol 19(1): 10–17.

    CAS  PubMed  Google Scholar 

  61. Saarto T, Taube T, Blomqvist C, et al. (2005) Three-year oral clodronate treatment does not impair mineralization of newly formed bone: a histomorphometric study. Calcif Tissue Int 77(2): 84–90.

    Article  CAS  PubMed  Google Scholar 

  62. Stopeck AT, Lipton A, Body JJ, et al. (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double-blind study. J Clin Oncol 28(35): 5132–5139.

    Article  CAS  PubMed  Google Scholar 

  63. Sundaresan N, Rothman A, Manhart K, Kelliher K (2002) Surgery for solitary metastases of the spine: rationale and results of treatment. Spine 27(16): 1802–1806.

    Article  PubMed  Google Scholar 

  64. Taylor RS, Fritzell P, Taylor RJ (2007) Balloon kyphoplasty in the management of vertebral compression fractures: an updated systematic review and meta-analysis. Eur Spine J 16(8): 1085–1100

    Article  PubMed Central  PubMed  Google Scholar 

  65. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. (2001) Essai comparatif randomisé en double insu clodronate oral 1 600 mg/j versus placebo chez des patientes avec métastases osseuses de cancer du sein. Bull Cancer 88(7): 701–707

    CAS  PubMed  Google Scholar 

  66. Van Poznak CH, Temin S, Yee GC, et al. (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29(9): 1221–1227.

    Article  PubMed  Google Scholar 

  67. Van Poznak CH, Von Roenn JH, Temin S (2011) American Society of Clinical Oncology Clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract 7(2): 117–121.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Vieillard MH, Thureau S (2013) Multidisciplinary meetings dedicated to bone metastases: a historical perspective and rationale. Réunions de concertation pluridisciplinaire (RCP) dediées aux métastases osseuses: historique et justification. Bull Cancer. 100(11):1135–1139

    PubMed  Google Scholar 

  69. Von Minckwitz G, Möbus V, Schneeweiss A et al. (2013) German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer. JCO 31(28):3531–3539

    Article  Google Scholar 

  70. Weill A, Kobaiter H, Chiras J (1998) Acetabulum malignancies: technique and impact on pain of percutaneous injection of acrylic surgical cement. Eur Radiol 8(1): 123–129.

    Article  CAS  PubMed  Google Scholar 

  71. Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2: CD003474.

    PubMed  Google Scholar 

  72. Yan T, Yin W, Zhou Q, et al. (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48(2): 187–195.

    Article  CAS  PubMed  Google Scholar 

  73. Zairi F, Arikat A, Allaoui M, et al. (2012) Minimally invasive decompression and stabilization for the management of thoracolumbar spine metastasis. J Neurosurg Spine 17(1): 19–23.

    Article  PubMed  Google Scholar 

Références électroniques

  1. Afssaps (2007) Recommandations sur la prise en charge buccodentaire des patients traités par bisphosphonate — http://ansm.sante.fr/

    Google Scholar 

  2. Stopeck ALA, Martín M, Body JJ, et al. (2011) Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2-year open-label extension treatment phase of a pivotal phase 3 study. http://www.sabcsorg/UserPortal/Documents/Abstract_Book_SABCS_20111215pdf. 2011; Abstract 136, SAC Congres 2011

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rhumatologie, Lille, France

    M. H. Vieillard

  2. Neuro-radiologie, Paris, France

    J. Chiras

  3. Biologie, Lyon, France

    P. Clézardin

  4. Oncologie, Nice, France

    J. -M. Ferrero & J. Barrière

  5. Oncologie, Paris, France

    P. Beuzeboc

Authors
  1. M. H. Vieillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Chiras
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Clézardin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. -M. Ferrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Barrière
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Beuzeboc
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Cet article fait l’objet d’un tableau synthetique (DOI 10.1007/s10269-013-2355-x).

About this article

Cite this article

Vieillard, M.H., Chiras, J., Clézardin, P. et al. Os, cible thérapeutique (RPC 2013). Oncologie 15, 673–686 (2013). https://doi.org/10.1007/s10269-013-2353-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-013-2353-z

Search

Navigation